Hence, CXCL13 has great potential to be developed as clinically-certified assays for the diagnosis of MS; however, it should be noted that intrathecal production of CXCL13 is not exclusively characteristic of MS neuroinflammation and may also be associated with other neuroinflammatory diseases (Alvarez et al., 2013; Irani, 2016). Here, CXCL13 is linked to myeloid sarcoma.